Abstract
Trypanosoma cruzi (T. cruzi) is the parasite that causes Chagas disease. Nifurtimox is the most used drug against the T. cruzi, this drug increases intermediaries nitro group, being mainly responsible for the high toxicity component, for this reason it is important to study new organic compounds and thus improve therapeutic strategies against Chagas disease. The electronic effects of ferrocenyl and cyrhetrenyl fragments were investigated by DFT calculation. A close correlation was found between HOMO–LUMO gap of nitro radical NO −2 with the experimental reduction potential found for nitro group and IC50 of two forms the T. cruzi (epimastigote and trypomastigote). The IC50 on human hepatoma cells is higher for both compounds compared to IC50 demonstrated in the two forms the T. cruzi, and additionally show reactive oxygen species release. The information obtained in this paper could generate two new drugs with anti-T. cruzi activity, but additional studies are needed.
Abbreviations
- ROS:
-
Reactive oxygen species
- T. cruzi :
-
Trypanosoma cruzi
- HepG2:
-
Human hepatoma cells
- NFX:
-
Nifurtimox
References
Arancibia R, Klahn H, Buono-core GE et al (2011) Synthesis, characterization and anti-Trypanosoma cruzi evaluation of ferrocenyl and cyrhetrenyl imines derived from 5-nitrofurane. J Organomet Chem. doi:10.1016/j.jorganchem.2011.06.038
Arancibia R, Hugo Klahn A, Buono-Core GE et al (2013) Organometallic schiff bases derived from 5-nitrothiophene and 5-nitrofurane: synthesis, crystallographic, electrochemical, ESR and antiTrypanosoma cruzi studies. J Organomet Chem 743:49–54. doi:10.1016/j.jorganchem.2013.06.014
Boiani M, Piacenza L, Hernndez P et al (2010) Mode of action of nifurtimox and N-oxide-containing heterocycles against Trypanosoma cruzi: is oxidative stress involved? Biochem Pharmacol 79:1736–1745. doi:10.1016/j.bcp.2010.02.009
Carter WO, Narayanan PK, Robinson JP (1994) Intracellular hydrogen peroxide and superoxide anion detection in endothelial cells. J Leukoc Biol 55:253–258
Circu ML, Aw TY (2010) Reactive oxygen species, cellular redox systems, and apoptosis. Free Radic Biol Med 48:749–762. doi:10.1016/j.freeradbiomed.2009.12.022
Dias LRS, Santos MB, De Albuquerque S et al (2007) Synthesis, in vitro evaluation, and SAR studies of a potential antichagasic 1H-pyrazolo[3,4-b]pyridine series. Bioorg Med Chem 15:211–219. doi:10.1016/j.bmc.2006.09.067
Docampo R (1990) Sensitivity of parasites to free radical damage by antiparasitic drugs. Chem Biol Interact 73:1–27. doi:10.1016/0009-2797(90)90106-W
Docampo R, Moreno SN (1986) Free radical metabolism of antiparasitic agents. Fed Proc 45:2471–2476
Docampo R, Mason RP, Mottley C, Muniz RP (1981) Generation of free radicals induced by nifurtimox in mammalian tissues. J Biol Chem 256:10930–10933
Dubin M, Moreno SN, Martino EE et al (1983) Increased biliary secretion and loss of hepatic glutathione in rat liver after nifurtimox treatment. Biochem Pharmacol 32:483–487. doi:10.1016/0006-2952(83)90527-0
González-Martin G, Ponce G, Inostroza V et al (1993) The disposition of nifurtimox in the rat isolated perfused liver: effect of dose size. J Pharm Pharmacol 45:72–74
Hasslocher-Moreno AM, do Brasil PE, de Sousa AS et al (2012) Safety of benznidazole use in the treatment of chronic Chagas’ disease. J Antimicrob Chemother 67:1261–1266. doi:10.1093/jac/dks027
Letelier ME, Izquierdo P, Godoy L et al (2004) Liver microsomal biotransformation of nitro-aryl drugs: mechanism for potential oxidative stress induction. J Appl Toxicol 24:519–525. doi:10.1002/jat.999
Manov I, Hirsh M, Iancu TC (2004) N-acetylcysteine does not protect HepG2 cells against acetaminophen-induced apoptosis. Basic Clin Pharmacol Toxicol 94:213–225. doi:10.1111/j.1742-7843.2004.pto940504.x
Maya JD, Cassels BK, Iturriaga-Vásquez P et al (2007) Mode of action of natural and synthetic drugs against Trypanosoma cruzi and their interaction with the mammalian host. Comp Biochem Physiol 146:601–620. doi:10.1016/j.cbpa.2006.03.004
Maya JD, Orellana M, Ferreira J et al (2010) Chagas disease: present status of pathogenic mechanisms and chemotherapy. Biol Res 43:323–331
Miller D, Hernandez S, Rodriguez De Armas L et al (2015) Tolerance of benznidazole in a United States chagas disease clinic. Clin Infect Dis 60:1237–1240. doi:10.1093/cid/civ005
Nogueira Silva JJ, Pavanelli WR, Gutierrez FRS et al (2008) Complexation of the anti-Trypanosoma cruzi drug benznidazole improves solubility and efficacy. J Med Chem 51:4104–4114. doi:10.1021/jm701306r
Nozaki T, Engel JC, Dvorak JA (1996) Cellular and molecular biological analyses of nifurtimox resistance in Trypanosoma cruzi. Am J Trop Med Hyg 55:111–117
Paes MC, Cosentino-Gomes D, de Souza CF et al (2011) The role of heme and reactive oxygen species in proliferation and survival of Trypanosoma cruzi. J Parasitol Res 2011:174614. doi:10.1155/2011/174614
Peloso EF, Gonçalves CC, Silva TM et al (2012) Tryparedoxin peroxidases and superoxide dismutases expression as well as ROS release are related to Trypanosoma cruzi epimastigotes growth phases. Arch Biochem Biophys 520:117–122. doi:10.1016/j.abb.2012.02.020
Piacenza L, Irigoín F, Alvarez MN et al (2007) Mitochondrial superoxide radicals mediate programmed cell death in Trypanosoma cruzi: cytoprotective action of mitochondrial iron superoxide dismutase overexpression. Biochem J 403:323–334. doi:10.1042/BJ20061281
Piacenza L, Zago MP, Peluffo G et al (2009) Enzymes of the antioxidant network as novel determiners of Trypanosoma cruzi virulence. Int J Parasitol 39:1455–1464. doi:10.1016/j.ijpara.2009.05.010
Porcal W, Hernández P, Aguirre G et al (2007) Second generation of 5-ethenylbenzofuroxan derivatives as inhibitors of Trypanosoma cruzi growth: synthesis, biological evaluation, and structure-activity relationships. Bioorg Med Chem 15:2768–2781. doi:10.1016/j.bmc.2007.01.009
Pugh AJ, Barve AJ, Falkner K et al (2009) Drug-induced hepatotoxicity or drug-induced liver injury. Clin Liver Dis 13:277–294
WHO (2015) Chagas disease (American trypanosomiasis). In: Word Health. Organ
Zhou L, Stewart G, Rideau E et al (2013) A class of 5-nitro-2-furancarboxylamides with potent trypanocidal activity against Trypanosoma brucei in vitro. J Med Chem 56:796–806. doi:10.1021/jm301215e
Author contribution
All authors have given approval to the final version of the manuscript.
Funding
This work was supported by the research grants from Fondo Nacional de Desarrollo Científico y Tecnológico—Fondecyt 11130007 (R.R-T.), 3140448 (C.E.), 1121078 (F.S.), 1120286 (R.A.), Millennium Institute on Immunology and Immunotherapy P09-016-F (F.S.) and UNAB DI-741-15/N (F.S.).
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Echeverría, C., Romero, V., Arancibia, R. et al. The characterization of anti-T. cruzi activity relationships between ferrocenyl, cyrhetrenyl complexes and ROS release. Biometals 29, 743–749 (2016). https://doi.org/10.1007/s10534-016-9953-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10534-016-9953-1